CBDCA: phase II evaluation in advanced colorectal carcinoma.
Carboplatin (CBDCA) (NSC-241240) was administered to 25 consecutive patients with measurable colorectal carcinomas. Twenty-four patients were previously untreated, with a median performance status of 80. The dose schedule was 400 mg/m2 every 28 days and was escalated to 450 mg/m2 if no side effects or grade I toxicities occurred. All patients are assessable for toxicity and response. No complete response was observed; one partial response, lasting 23 weeks, was noted. Toxicity was primarily hematological. Neither auditory nor renal toxicities were observed. CBDCA administered in the above schedule has little therapeutic efficacy in previously untreated colorectal carcinoma patients.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D006801:Humans; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy*; D013997:Time Factors
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D016190:Carboplatin